Table 4.
Sample size (participants) and main outcomes of the different studies.
| Study | Sample Size | Analyzed Parameters (Time for Measurement) |
Main Outcomes |
|---|---|---|---|
| Nieman et al., 2013 [32] | 28 | CK, LDH, Mb (immediately after exercise execution) |
↑CK, ↑LDH, ↑Mb |
| Shanely et al., 2014 [33] | 50 | CK, LDH, Mb (immediately after exercise execution) |
=CK, =LDH, =Mb |
| Parsaie et al., 2019 [34] | 22 | CK, LDH (immediately after exercise execution) |
=CK, =LDH |
| Ashtary-Larky et al., 2020 [35] | 14 | CK, LDH (1 h after exercise execution) |
=CK, =LDH |
| Pilch et al., 2020 [36] | 60 | CK, LDH, Mb (1 h after exercise execution) |
↓CK, ↓LDH, ↓Mb * |
| Żebrowska et al., 2020 [37] | 24 | CK, LDH, Mb (1 h after exercise execution) |
↓CK, ↓LDH, ↓Mb |
Abbreviations and symbols used: CK, creatine kinase; LDH, lactate dehydrogenase; Mb, myoglobin, (↑) significant increased levels after intervention (negative outcome) in the supplemented group compared to placebo), (↓) significant decreased levels after intervention (positive outcome) in the supplemented group compared to the placebo group, (=) not significant differences after the intervention comparing experimental group to placebo. (*) Observed after 3 months of supplementation in the group with suboptimal levels of circulating vitamin D at the beginning of the study compared to a non-supplemented group. Articles include other outcomes not presented in the table.